- Exchange: Copenhagen
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Novo Nordisk A/S
Add to PortfolioNOVOB:DC
826.500 DKK 12.500 1.49%As of 11:04:51 ET on 05/29/2012.
Snapshot for Novo Nordisk A/S (NOVOB)
| Open: | 831.500 | Day's Range: | 822.500 - 838.000 | Volume: | 710,588 | Bid: | 826.500 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 839.000 | 52wk Range: | 507.000 - 866.500 | 1-Yr Rtn: | +29.69% | Ask: | 827.000 |
Stock Chart for NOVOB
Key Statistics for NOVOB
| Current P/E Ratio (ttm) | 26.2327 |
|---|---|
| Estimated P/E (12/2012) | 23.2391 |
| Earnings Per Share (DKK) (ttm) | 31.5065 |
| Est. EPS (DKK) (12/2012) | 35.5650 |
| Est. PEG Ratio | 1.4631 |
| Market Cap (M DKK) | 462,840.00 |
| Shares Outstanding (M) | 452.51 |
| Enterprise Value (M DKK) (ttm) | 450,430.99 |
| Enterprise Value/EBITDA (ttm) | 17.42 |
| Price/Book (mrq) | 14.0968 |
| Price/Sale (ttm) | 6.7837 |
| Dividend Indicated Gross Yield | 1.6939 |
| Next Earnings Announcement | 08/09/2012 |
More NOVOB Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for NOVOB
- Operating
- Investing
- Financing (M/DKK)
Company Profile & Key Executives for NOVOB
Novo Nordisk A/S develops, produces, and markets pharmaceutical products. The Company focuses on diabetes care and offers insulin delivery systems and other diabetes products. Novo Nordisk also works in areas such as haemostatis management, growth disorders, and hormone replacement therapy. The Company offers educational and training materials. Novo Nordisk markets worldwide.
| Sten ScheibyeChairman | Goran A AndoVice Chairman |
| Lars Rebien SoerensenPresident/CEO | Jesper BrandgaardExec VP/CFO |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page